CytomX Therapeutics, Inc. (CTMX)
| Market Cap | 808.41M +135.7% |
| Revenue (ttm) | 18.30M -87.0% |
| Net Income | -82.66M |
| EPS | -0.45 |
| Shares Out | 217.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,297,746 |
| Open | 3.640 |
| Previous Close | 3.680 |
| Day's Range | 3.530 - 3.725 |
| 52-Week Range | 1.900 - 8.210 |
| Beta | 2.14 |
| Analysts | Strong Buy |
| Price Target | 12.25 (+230.19%) |
| Earnings Date | Aug 6, 2026 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclin... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $12.25, which is an increase of 230.19% from the latest price.
News
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manag...
CytomX Therapeutics gets Fast Track Designation for Varseta-M
CytomX Therapeutics (CTMX) announced that the FDA has granted Fast Track Designation to Varseta-M for the treatment of patients with relapsed/refractory metastatic colorectal cancer. Varseta-M is an a...
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2...
CytomX Therapeutics price target lowered to $11 from $12 at JPMorgan
JPMorgan lowered the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $12 and keeps an Overweight rating on the shares.
CytomX Therapeutics price target lowered to $14 from $15 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on CytomX Therapeutics (CTMX) to $14 from $15 and keeps a Buy rating on the shares following the Q2 update focusing…
CytomX Therapeutics reports Q2 EPS (9c), consensus (10c)
Reports Q2 revenue $1.42M, consensus $12.34M. “CytomX had a productive second quarter as we advanced and broadened the Varseta-M program, the only EpCAM-directed antibody drug conjugate (ADC) in clini...
CytomX Therapeutics Earnings Call Transcript: Q2 2026
Varseta-M's development in CRC and other GI cancers advanced with strong clinical and operational progress, while financials reflect a robust cash position and increased R&D investment. Key milestones include a major Regeneron collaboration expansion and new executive hires.
CytomX Therapeutics Quarterly report: Q2 2026
CytomX Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
CytomX Therapeutics Earnings release: Q2 2026
CytomX Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Pha...
CytomX Therapeutics appoints Alejandra Carvajal as chief legal officer
CytomX Therapeutics (CTMX) announced the appointment of Alejandra Carvajal as chief legal officer. In this role, Carvajal will support the company’s strategic, operational, and pipeline initiatives. M...
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appoint...
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wil...
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appoint...
CytomX Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The Probody platform enables tumor-selective biologics, with Varseta-M showing strong efficacy and safety in late-line CRC and plans for expansion into earlier lines and other tumors. The Regeneron partnership and CX-801 program further broaden the pipeline and funding base.
CytomX Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company highlighted major progress in its Probody platform and expanded its Regeneron collaboration, securing significant funding. Varseta-M demonstrated strong efficacy and manageable safety in late-line CRC, with pivotal trials and combination studies planned.
CytomX Therapeutics expands licensing agreement with Regeneron
CytomX Therapeutics (CTMX) announced an expansion of its collaboration and licensing agreement with Regeneron Pharmaceuticals (REGN) to create conditionally-activated bispecific cancer therapies utili...
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -
CytomX Therapeutics to Present at Upcoming June Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that managem...
CytomX Therapeutics initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of CytomX Therapeutics (CTMX) with an Outperform rating and $6 price target The company owns the only “de-risked” epithelial cell adhesion molecule antibody-drug conj...
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointm...
CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on CytomX Therapeutics (CTMX) to $11 from $17 and keeps a Buy rating on the shares. The firm cites the company’s financing-related dilution…
CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)
Reports Q1 revenue $10.26M, consensus $4.68M. “CytomX has continued to gain tremendous momentum in 2026 and we remain highly focused on executing against the multiple layers of potential value creatio...
CytomX Therapeutics Earnings Call Transcript: Q1 2026
Strong clinical progress for Varseta-M in late-line CRC, robust cash position, and focused capital allocation support advancement into pivotal studies. Next major data update expected in the second half of 2026, with expansion into new indications and combinations underway.
CytomX Therapeutics Quarterly report: Q1 2026
CytomX Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.